Developing novel precision oncology therapeutics
Our mission is to develop a broad pipeline of next-generation precision oncology therapeutics in areas of high unmet medical need. Our vision is to become a global leader in personalized oncology medicine by leveraging our expertise in clinical research, development and product registration.
AnHeart’s pipeline consists of three clinical stage assets:
- Taletrectinib AB-106: a next-generation ROS1 and NTRK inhibitor currently in Phase 2
- mIDH1 inhibitor AB-218: entering Phase 2 for lower-grade glioma, cholangiocarcinoma, AML and other tumors
- AXL inhibitor AB-329: in Phase 1 for overcoming checkpoint inhibitor or EGFRi resistance in various tumors